SHILPAMED943.00

Shilpa Medicare Ltd.

· Pharma & Health
₹ CrorePeersNATCOPHARMSPARCSTARRUBICONSUPRIYATHYROCAREVIYASHPARKHOSPSMcap ₹18,445 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+11.7+19.6
EBITDA Growth+29.7+37.1
EBIT Growth+49.4+54.4
Net Income Growth+145.6+210.8
EPS Growth+119.1+54.7
Total Assets Growth+7.0+11.9
Total Equity Growth+31.3+9.6
Cash from Operations Growth-2.3+158.9
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.